The US Food and Drug Administration (FDA) has approved ruxolitinib (Jakafi) for treatment of chronic graft-versus-host disease (GVHD) in adults and in pediatric patients 12 years and older who have already had one or two lines of systemic therapy. The product, a JAK inhibitor first marketed for use in myelofibrosis, is already approved for acute GVHD […]